keyword
https://read.qxmd.com/read/38650534/future-perspectives-of-radiation-therapy-for-hodgkin-lymphoma-risk-adapted-response-adapted-and-safer-than-before
#21
REVIEW
Jessica Saddi, Amelia Barcellini, Manuel Gotti, Alessandro Mazzacane, Alessandra Tolva, Tanja Lazic, Luca Arcaini, Marco Zecca, Ester Orlandi, Andrea Riccardo Filippi
Classical Hodgkin lymphoma is a lymphoproliferative disease with a good prognosis mainly seen in young people. Nevertheless secondary malignancy, cardiac disease and infertility may affect the long survivors with significant impact on quality of life, morbidity and overall survival. In the last decades several treatment strategies were evaluated to reduce the toxicity of first line treatment such as avoiding radiotherapy or its reduction in terms of dosage and extension. Many trials including interim Positron Emission Tomography evaluation fail to compare efficacy between combined modality treatment versus chemotherapy alone in particular in early stage disease...
May 2024: Hematological Oncology
https://read.qxmd.com/read/38650005/heterodimerization-of-t-cell-engaging-bispecific-antibodies-to-enhance-specificity-against-pancreatic-ductal-adenocarcinoma
#22
JOURNAL ARTICLE
Alan W Long, Hong Xu, Brian H Santich, Hongfen Guo, Sayed Shahabuddin Hoseini, Elisa de Stanchina, Nai-Kong V Cheung
BACKGROUND: EGFR and/or HER2 expression in pancreatic cancers is correlated with poor prognoses. We generated homodimeric (EGFRxEGFR or HER2xHER2) and heterodimeric (EGFRxHER2) T cell-engaging bispecific antibodies (T-BsAbs) to direct polyclonal T cells to these antigens on pancreatic tumors. METHODS: EGFR and HER2 T-BsAbs were constructed using the 2 + 2 IgG-[L]-scFv T-BsAbs format bearing two anti-CD3 scFvs attached to the light chains of an IgG to engage T cells while retaining bivalent binding to tumor antigens with both Fab arms...
April 23, 2024: Journal of Hematology & Oncology
https://read.qxmd.com/read/38647418/therapeutic-efficacy-of-ras-inhibitor-trametinib-using-a-juvenile-myelomonocytic-leukemia-patient-derived-xenograft-model
#23
JOURNAL ARTICLE
Alex Q Lee, Hiroaki Konishi, Masami Ijiri, Yueju Li, Arun Panigrahi, Jeremy Chien, Noriko Satake
Juvenile myelomonocytic leukemia (JMML) is an aggressive pediatric leukemia with few effective treatments and poor outcomes even after stem cell transplantation, the only current curative treatment. We developed a JMML patient-derived xenograft (PDX) mouse model and demonstrated the in vivo therapeutic efficacy and confirmed the target of trametinib, a RAS-RAF-MEK-ERK pathway inhibitor, in this model. A PDX model was created through transplantation of patient JMML cells into mice, up to the second generation, and successful engraftment was confirmed using flow cytometry...
April 22, 2024: Pediatric Hematology and Oncology
https://read.qxmd.com/read/38646358/pediatric-prostatic-alveolar%C3%A2-rhabdomyosarcoma-presenting-with-metastatic-spinal-cord-compression-in-the-thoracic-spine-a-case-report-and-review-of-the-literature
#24
Matthew T Perry, Andrew J Witten, Majeed Marwan, Alexander Vortmeyer, Jignesh Tailor
Rhabdomyosarcoma (RMS) is a pediatric malignancy with a variable prognosis depending on tumor stage and genotype. There has been a significant improvement in survival rates over the past decades. However, aggressive variants can metastasize to locations that are difficult to treat. We report a case of prostatic alveolar rhabdomyosarcoma with metastases to the bone marrow and thoracic spine in a child. The patient was treated with a multimodal approach that included surgical resection of the epidural mass; the administration of vincristine, dactinomycin, and cyclophosphamide; and radiotherapy...
March 2024: Curēus
https://read.qxmd.com/read/38646245/a-case-of-acute-kidney-injury-proteinuria-and-thrombotic-microangiopathy-associated-with-sunitinib-therapy-in-metastatic-pancreatic-neuroendocrine-tumor
#25
Lawanya Singh, Daniel Matassa, Sharon Li
There have been rare reports of patients developing nephrotic syndrome and thrombotic microangiopathy (TMA) with tyrosine kinase inhibitors (TKIs). We present the case of a patient with a history of metastatic pancreatic neuroendocrine tumor (pNET), treated with sunitinib, who rapidly developed TMA and acute kidney injury. The patient was successfully treated with cessation of sunitinib and administration of steroids. This case report contributes to the growing body of literature surrounding the rare side effects of TKIs and our experience with the management of these adverse events...
March 2024: Curēus
https://read.qxmd.com/read/38644266/-chinese-expert-consensus-on-the-management-of-clinical-pathway-and-adverse-events-of-trastuzumab-deruxtecan-2024-edition
#26
JOURNAL ARTICLE
(no author information available yet)
Trastuzumab deruxtecan (T-DXd) is one of the new generation antibody-drug conjugates (ADCs) targeting human epidermal growth factor receptor 2 (HER-2) with bystander effect. T-DXd can not only significantly improve the survival of HER-2-positive advanced breast cancer patients, but also enable advanced breast cancer patients with low HER-2 expression to benefit from HER-2-targeted therapy. T-DXd has been approved by the National Medical Products Administration (NMPA) for the treatment of HER-2-positive or HER-2-low breast cancer patients...
April 23, 2024: Zhonghua Zhong Liu za Zhi [Chinese Journal of Oncology]
https://read.qxmd.com/read/38643356/safety-and-effectiveness-of-clofarabine-in-japanese-patients-with-relapsed-refractory-acute-lymphoblastic-leukaemia-a-post-marketing-surveillance-study
#27
JOURNAL ARTICLE
Hirotaka Kazama, Satoshi Nishina, Takeshi Seto
OBJECTIVE: Clofarabine is used to treat acute lymphoblastic leukaemia, but evidence of its safety and effectiveness in Japanese patients is limited. We evaluated the safety and effectiveness of clofarabine in patients with relapsed/refractory acute lymphoblastic leukaemia in real-world clinical practice in Japan. METHODS: An observational, multicenter, post-marketing, all-case surveillance was conducted for safety. Effectiveness analyses were conducted in patients aged ≤21 years and those treated with clofarabine monotherapy and combination therapy (clofarabine plus etoposide and cyclophosphamide)...
April 20, 2024: Japanese Journal of Clinical Oncology
https://read.qxmd.com/read/38643301/impact-of-early-access-reform-on-oncology-innovation-in-france-approvals-patients-and-costs
#28
JOURNAL ARTICLE
Tess Martin, Catherine Rioufol, Bertrand Favier, Nicolas Martelli, Isabelle Madelaine, Christos Chouaid, Isabelle Borget
BACKGROUND: An ambitious reform of the early access (EA) process was set up in July 2021 in France, aiming to simplify procedures and accelerate access to innovative drugs. OBJECTIVE: This study analyzes the characteristics of oncology drug approvals through the EA process and its impact on real-life data for oncology patients. METHODS: The number and characteristics of EA demands concerning oncology drugs submitted to the National Health Authority (HAS, Haute Autorité de Santé) were reviewed until 31 December 2022...
April 20, 2024: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
https://read.qxmd.com/read/38642726/what-is-the-role-of-physical-exercise-in-the-era-of-cancer-prehabilitation-a-systematic-review
#29
REVIEW
Nicole Del Bianco, Anita Borsati, Linda Toniolo, Christian Ciurnielli, Lorenzo Belluomini, Jessica Insolda, Marco Sposito, Michele Milella, Federico Schena, Sara Pilotto, Alice Avancini
PURPOSE: Exercise before surgery, as part of prehabilitation, aiming to enhance patients' functional and physiological capacity, has become widespread, necessitating an in-depth understanding. METHODS: A systematic search was conducted on Pubmed, Cochrane, and Scopus to examine the effect of exercise as prehabilitation, alone or in combination with other interventions, in patients with cancer. Interventional studies applying a single-arm, randomized controlled, or nonrandomized design were included...
April 18, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38641485/mantle-cell-lymphoma-under-the-scope-of-personalized-medicine-perspective-and-directions
#30
REVIEW
Lara Gallucci Figorelle, Peterson Tiago Galvão, Felipe Matheus Ribeiro de Lima, Patricia Marimon, Nathalia Pentagna, Cristiane Milito, Rony Schaffel, Katia Carneiro
Mantle cell lymphoma (MCL) is a rare, incurable non-Hodgkin's lymphoma characterized by naive B cells infiltrating the lymphoid follicle's mantle zone. A key feature of MCL is the cytogenetic abnormality t(11;14) (q13:q14), found in 95% of cases, leading to Cyclin D1 overexpression resulting in uncontrolled cell cycle progression and genetic instability. Occasionally, Cyclin D2 or D3 overexpression can substitute for Cyclin D1, causing similar effects. The transcription factor SOX11 is a hallmark of classical Cyclin D1-positive MCL and also in cases without the typical t(11;14) abnormality, making it an important diagnostic marker...
March 27, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38641134/research-update-for-ferroptosis-and-cholangiocarcinoma
#31
REVIEW
Shengfeng Fu, Qinyang Zhang, Changhe Zhang
Cholangiocarcinoma (CCA) is the second most common hepatobiliary malignancy after hepatocellular carcinoma. Due to the poor treatment effect and high mortality rate of CCA, it is of great significance to explore new therapeutic targets. Ferroptosis is a type of cell death caused by iron-dependent cell oxidative injury, which is closely related to the occurrence and development of numerous diseases. Novel ideas for the prevention and treatment of related diseases have been provided by ferroptosis, which has become a focus of research in recent years...
April 17, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38637871/bilateral-wilms-tumor-with-anaplasia-a-report-from-the-children-s-oncology-group-study-aren0534
#32
JOURNAL ARTICLE
Rodrigo L P Romao, Jennifer H Aldrink, Lindsay A Renfro, Elizabeth A Mullen, Andrew J Murphy, Jack Brzezinski, Marcus M Malek, Daniel J Benedetti, Nicholas G Cost, Ethan Smith, Jeffrey S Dome, Andrew M Davidoff, Amy Treece, Lauren N Parsons, Conrad V Fernandez, Brett Tornwall, Robert C Shamberger, Arnold Paulino, John A Kalapurakal, James I Geller, Peter F Ehrlich
INTRODUCTION: The purpose of this study is to examine the outcomes in children with anaplastic bilateral Wilms tumor (BWT) from study AREN0534 in order to define potential prognostic factors and areas to target in future clinical trials. METHODS: Demographic and clinical data from AREN0534 study patients with anaplasia (focal anaplasia [FA], or diffuse anaplasia [DA]) were compared. Event-free survival (EFS) and overall survival (OS) were reported using Kaplan-Meier estimation with 95% confidence bands, and differences in outcomes between FA and DA compared using log-rank tests...
April 18, 2024: Pediatric Blood & Cancer
https://read.qxmd.com/read/38634996/an-unfavorable-and-a-successful-pregnancy-outcome-during-and-after-treatment-of-gamma-heavy-chain-disease
#33
JOURNAL ARTICLE
Masataka Hosoi, Kazunori Ueno, Jun Kikuchi, Jun Miyauchi, Reina Ooka, Kaito Takikawa, Yuya Arai, Misato Kikuchi, Takuro Watanabe
Gamma heavy chain disease (gHCD) is a rare B-cell lymphoproliferative disorder that mostly occurs after childbearing age. Here we report the first case of gHCD in a pregnant patient that was diagnosed in the second trimester, and another pregnancy in the same patient after initial treatment for gHCD. The former pregnancy ended in intrauterine fetal death, believed to be caused by insufficient maternal blood flow due to multiple placental infarcts. The latter pregnancy course was uneventful. Although we cannot rule out the possibility that the poor outcome of the former pregnancy was due to an unfortunate complication independent of gHCD, the courses of these pregnancies suggest that non-lymphomatous gamma heavy chain may have a significant impact on pregnancy and that its removal by treatment may improve outcomes...
April 18, 2024: International Journal of Hematology
https://read.qxmd.com/read/38632943/external-validation-of-the-risk-assessment-model-of-venous-thromboembolism-in-multicenter-internal-medicine-inpatients
#34
MULTICENTER STUDY
Xiaolan Chen, Hongning Shi, Jiaqi Chang, Wenjia Guo, Yuanhua Yang, Yong Wang, Lei Pan
To external validate the risk assessment model (RAM) of venous thromboembolism (VTE) in multicenter internal medicine inpatients. We prospectively collected 595 internal medical patients (310 with VTE patients, 285 non-VTE patients) were from Beijing Shijitan Hospital, Beijing Chaoyang Hospital, and the respiratory department of Beijing Tsinghua Changgeng Hospital from January 2022 to December 2022 for multicenter external validation. The prediction ability of Caprini RAM, Padua RAM, The International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) RAM, and Shijitan (SJT) RAM were compared...
2024: Clinical and Applied Thrombosis/hemostasis
https://read.qxmd.com/read/38629258/off-label-prescribing-of-immune-checkpoint-inhibitor-therapy-at-a-single-pediatric-cancer-center
#35
JOURNAL ARTICLE
Ajami Gikandi, Susan N Chi, Kee Kiat Yeo, Allison F O'Neill, David S Shulman, Steven G DuBois, Natalie B Collins
BACKGROUND: Immune checkpoint inhibitors (ICI) have improved outcomes in a variety of adult cancers and are prescribed with increasing frequency across oncology. However, patterns of off-label use of ICI in pediatrics remain unclear. METHODS: This is a single-institution, retrospective cohort study evaluating off-label ICI use in pediatric and young adult patients with cancer treated at our institution from 2014 to 2022. Response was based on clinician assessment derived from clinical records...
April 2024: Cancer Medicine
https://read.qxmd.com/read/38627882/event-free-survival-in-relapsed-and-refractory-rhabdomyosarcoma-treated-on-cooperative-group-phase-ii-trials-a-report-from-the-children-s-oncology-group
#36
JOURNAL ARTICLE
Jonathan Metts, Wei Xue, Zhengya Gao, Sapna Oberoi, Aaron R Weiss, Rajkumar Venkatramani, Douglas J Harrison
BACKGROUND: Novel therapies are needed for relapsed and refractory rhabdomyosarcoma (RRMS). Phase II clinical trials in RRMS have typically utilized radiologic response as the primary activity endpoint, an approach that poses several limitations in RRMS. In this analysis, we aimed to estimate an event-free survival (EFS) endpoint for RRMS that could be used as a benchmark for future studies. PROCEDURE: We performed a retrospective study of patients with RRMS enrolling on 13 single-agent phase II Children's Oncology Group and legacy group trials from 1997 to 2016...
April 16, 2024: Pediatric Blood & Cancer
https://read.qxmd.com/read/38626849/the-involvement-of-ros-regulated-programmed-cell-death-in-hepatocellular-carcinoma
#37
REVIEW
Hanchen Cai, Ziqi Meng, Fujun Yu
Reactive oxidative species (ROS) is a crucial factor in the regulation of cellular biological activity and function, and aberrant levels of ROS can contribute to the development of a variety of diseases, particularly cancer. Numerous discoveries have affirmed that this process is strongly associated with "programmed cell death (PCD)," which refers to the suicide protection mechanism initiated by cells in response to external stimuli, such as apoptosis, autophagy, ferroptosis, etc. Research has demonstrated that ROS-induced PCD is crucial for the development of hepatocellular carcinoma (HCC)...
April 14, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38626848/the-crosstalk-between-oncogenic-signaling-and-ferroptosis-in-cancer
#38
REVIEW
Qianghu Pang, Zhirou Tang, Lianxiang Luo
Ferroptosis, a novel form of cell death regulation, was identified in 2012. It is characterized by unique features that differentiate it from other types of cell death, including necrosis, apoptosis, autophagy, and pyroptosis. Ferroptosis is defined by an abundance of iron ions and lipid peroxidation, resulting in alterations in subcellular structures, an elevation in reactive oxygen species (ROS), a reduction in glutathione (GSH) levels, and an augmentation in Fe (II) cytokines. Ferroptosis, a regulated process, is controlled by an intricate network of signaling pathways, where multiple stimuli can either enhance or hinder the process...
April 16, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38625410/platinum-based-adjuvant-chemoradiotherapy-versus-adjuvant-radiotherapy-in-patients-with-head-and-neck-adenoid-cystic-carcinoma
#39
JOURNAL ARTICLE
Zichen Qiu, Zheng Wu, Xiong Zhou, Minchuan Lin, Yong Su, Yalan Tao
PURPOSE: The objective of the study was to assess the effectiveness and toxicity of platinum-based adjuvant chemoradiotherapy (POCRT) in comparison to postoperative radiotherapy (PORT) in patients with head and neck adenoid cystic carcinoma (HNACC). MATERIALS AND METHODS: This retrospective study analyzed patients diagnosed with HNACC at our center between January 2010 and April 2020. A 1:1 propensity score matching method was used to create a matched cohort. RESULTS: In this study, 206 patients were analyzed, with 147 patients (71...
April 16, 2024: Journal of Cancer Research and Clinical Oncology
https://read.qxmd.com/read/38625382/-clinical-acute-and-emergency-medicine-curriculum-focus-on-internal-medicine-recommendations-for-advanced-training-in-internal-medicine-in-the-emergency-department
#40
REVIEW
Hans-Jörg Busch, Sebastian Wolfrum, Guido Michels, Matthias Baumgärtel, Klaus-Friedrich Bodmann, Michael Buerke, Volker Burst, Philipp Enghard, Georg Ertl, Wolf Andreas Fach, Frank Hanses, Hans Jürgen Heppner, Carsten Hermes, Uwe Janssens, Stefan John, Christian Jung, Christian Karagiannidis, Michael Kiehl, Stefan Kluge, Alexander Koch, Matthias Kochanek, Peter Korsten, Philipp M Lepper, Martin Merkel, Ursula Müller-Werdan, Martin Neukirchen, Alexander Pfeil, Reimer Riessen, Wolfgang Rottbauer, Sebastian Schellong, Alexandra Scherg, Daniel Sedding, Katrin Singler, Marcus Thieme, Christian Trautwein, Carsten Willam, Karl Werdan
In Germany, physicians qualify for emergency medicine by combining a specialty medical training-e.g. internal medicine-with advanced training in emergency medicine according to the statutes of the State Chambers of Physicians largely based upon the Guideline Regulations on Specialty Training of the German Medical Association. Internal medicine and their associated subspecialities represent an important column of emergency medicine. For the internal medicine aspects of emergency medicine, this curriculum presents an overview of knowledge, skills (competence levels I-III) as well as behaviours and attitudes allowing for the best treatment of patients...
April 16, 2024: Medizinische Klinik, Intensivmedizin und Notfallmedizin
keyword
keyword
97492
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.